# RinuaGene Biotechnology

Source: https://onco.cc/companies/rinuagene-biotechnology/  
OnCo record `rinuagene-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RinuaGene develops mRNA medicines. Its lead product, RG002, is a therapeutic vaccine meant to make the immune system clear cervical precancer caused by HPV types 16 and 18, before it can turn into cancer.

## Summary

RinuaGene Biotechnology Co., Ltd., in BioBay Industry Park, Suzhou Industrial Park, China, was founded in 2021, according to the company, to develop RNA therapeutics and vaccines on an end-to-end mRNA and lipid nanoparticle platform. Its lead programme RG002 Injection is a therapeutic HPV mRNA vaccine for HPV-associated high-grade squamous intraepithelial lesions, persistent HPV infection and HPV-associated cancers; the company announced US FDA clearance followed by China NMPA CDE IND approval in December 2024. A phase 1/2 study in HPV 16- or 18-associated cervical intraepithelial neoplasia grade 2 or 3 is registered (NCT06273553). Related products RG002-02 to RG002-04 target the same lesions and respiratory papillomatosis, and the company also lists protein-replacement and prophylactic influenza and RSV vaccine programmes. In October 2026 it announced a collaboration with the Medicines Patent Pool under the WHO-led mRNA technology transfer programme. Founded in 2021, according to the company. Its first registered study, NCT06273553, in cervical precancer, was posted on ClinicalTrials.gov in February 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: RinuaGene
- HQ: Suzhou
- Type: biotech
- Website: https://www.rinuagene.com/

## Notes

- Read on 29 October 2026: rinuagene.com home and pipeline pages and the December 2024 IND release. Financing not stated on the pages read.
- RinuaGene is a general mRNA company; it is included because its lead clinical programme treats cervical precancer and is listed for HPV-associated cancer. Its registered study is in precancer (CIN2/3), not invasive cancer, so the cervical cancer link is to the disease being prevented.
- Trial facts from the ClinicalTrials.gov record NCT06273553, read on 29 October 2026.

## Sources

- Official website: https://www.rinuagene.com/
- Pipeline: https://www.rinuagene.com/pipeline/
- ClinicalTrials.gov: phase 1/2 trial of RG002 in HPV 16/18 CIN2/3 (NCT06273553): https://clinicaltrials.gov/study/NCT06273553

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Cancer interception vaccines](https://onco.cc/technologies/interception-vaccination/)

---
JSON: https://onco.cc/api/v1/entities/rinuagene-biotechnology.json